Arcus Biosciences Inc (RCUS) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

Total Revenue Chart for Arcus Biosciences Inc

Arcus Biosciences Inc (RCUS) revenue for FY2025 was USD 247.0M, a -4.3% change from FY2024. Arcus Biosciences Inc's revenue moved from USD 0.00 in 2016 to USD 247.0M in 2025 over 9 years. Earnings per share moved from USD -0.73 in 2016 to USD -3.71 in 2022. Revenue compound annual growth rate: 5-year CAGR of 25.9%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$2.33B
Implied Share Price
$18.54
Enterprise Value
$2.55B
Revenue (TTM)
$117.00M
EBITDA
-$476.00M
Profit Margin
0.00%
Trailing P/E
—
Forward P/E
0.00
Price/Book (MRQ)
6.76
Price/Sales (TTM)
19.93
EV/EBITDA
3.96
EV/Revenue
21.80
Dividend Yield
—
Book Value
$3.65
Free Cash Flow (FY2025)
-$484.00M
Free Cash Flow Yield
-20.76%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.